Wellington Shields Capital Management LLC increased its holdings in Abbott Laboratories (NYSE:ABT) by 5.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,518 shares of the healthcare product maker’s stock after acquiring an additional 1,600 shares during the quarter. Wellington Shields Capital Management LLC’s holdings in Abbott Laboratories were worth $1,581,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of ABT. Harvey Investment Co. LLC increased its stake in shares of Abbott Laboratories by 0.6% in the 1st quarter. Harvey Investment Co. LLC now owns 248,881 shares of the healthcare product maker’s stock worth $11,053,000 after acquiring an additional 1,580 shares in the last quarter. Farmers & Merchants Investments Inc. increased its stake in shares of Abbott Laboratories by 7.6% in the 1st quarter. Farmers & Merchants Investments Inc. now owns 103,815 shares of the healthcare product maker’s stock worth $4,610,000 after acquiring an additional 7,309 shares in the last quarter. Lodestar Investment Counsel LLC IL increased its stake in shares of Abbott Laboratories by 4.2% in the 1st quarter. Lodestar Investment Counsel LLC IL now owns 267,771 shares of the healthcare product maker’s stock worth $11,892,000 after acquiring an additional 10,731 shares in the last quarter. Somerset Trust Co increased its stake in shares of Abbott Laboratories by 3.3% in the 1st quarter. Somerset Trust Co now owns 29,683 shares of the healthcare product maker’s stock worth $1,318,000 after acquiring an additional 939 shares in the last quarter. Finally, Capital Investment Advisors LLC increased its stake in shares of Abbott Laboratories by 16.4% in the 1st quarter. Capital Investment Advisors LLC now owns 8,849 shares of the healthcare product maker’s stock worth $393,000 after acquiring an additional 1,248 shares in the last quarter. Institutional investors own 71.66% of the company’s stock.

In other news, insider Jared Watkin sold 552 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $47.97, for a total transaction of $26,479.44. Following the completion of the transaction, the insider now directly owns 47,090 shares of the company’s stock, valued at approximately $2,258,907.30. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Sharon J. Bracken sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $49.16, for a total value of $98,320.00. Following the transaction, the insider now directly owns 28,806 shares of the company’s stock, valued at $1,416,102.96. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 218,702 shares of company stock valued at $10,837,658. Corporate insiders own 0.76% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Wellington Shields Capital Management LLC Raises Position in Abbott Laboratories (ABT)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/11/wellington-shields-capital-management-llc-raises-position-in-abbott-laboratories-abt.html.

Shares of Abbott Laboratories (NYSE:ABT) traded up 0.65% during mid-day trading on Monday, hitting $52.36. 1,886,975 shares of the stock were exchanged. The stock has a market cap of $90.97 billion, a PE ratio of 73.33 and a beta of 1.06. The stock’s 50 day moving average is $49.78 and its 200-day moving average is $46.71. Abbott Laboratories has a 12 month low of $37.38 and a 12 month high of $52.60.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 20th. The healthcare product maker reported $0.62 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.60 by $0.02. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The business had revenue of $6.64 billion for the quarter, compared to analyst estimates of $6.63 billion. During the same quarter in the prior year, the firm posted $0.55 EPS. The business’s quarterly revenue was up 24.5% compared to the same quarter last year. On average, analysts anticipate that Abbott Laboratories will post $2.49 EPS for the current year.

Several analysts recently commented on the stock. BMO Capital Markets reissued a “hold” rating and set a $53.00 price objective on shares of Abbott Laboratories in a research report on Friday, September 1st. Citigroup Inc. assumed coverage on shares of Abbott Laboratories in a research report on Thursday, August 17th. They set a “neutral” rating and a $53.00 price objective on the stock. Cowen and Company reissued a “buy” rating and set a $55.00 price objective on shares of Abbott Laboratories in a research report on Thursday, August 17th. BidaskClub downgraded shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, August 6th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $58.00 price objective on shares of Abbott Laboratories in a research report on Thursday, August 3rd. Seven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $52.50.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Stock Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related stocks with our FREE daily email newsletter.